Medication Possession Ratio (MPR) for ACEI/ARB therapy for individuals with Chronic Kidney Disease (CKD) and/or diabetes mellitus and hypertension.
Measure Specs
General Information
Numerator
The sum of the days supply that fall within the measurement window for an ACEI/ARB fill for each patient in the denominator.
Time window: Anytime during the measurement period (12 months)
MPR Numerator:
1. New users: For patients with no prescriptions in the 180 days prior to the measurement period, sum of:
Days’ supply of all medications from the first prescription until the end of the measurement period.
**Remove the days’ supply that extend past the end of the measurement period.
2. Continuous users: For patients with 1 or more prescriptions in the 180 days prior to the measurement period, sum of:
Days’ supply of all medications in the measurement period
**Remove the days supply that extends past the end of the measurement period and add days supply from the previous period that apply to the current period.
Denominator
Beneficiaries with CKD stages 1-4 and/or diabetes mellitus and hypertension (HTN) identified during the measurement period with at least one Part D claim for an ACEI/ARB.
Time window: Anytime during the measurement period (12 consecutive months)
MPR Denominator:
1. New users: Number of days from the first prescription to the end of measurement period.
2. Continuous users: Number of days from the beginning to the end of the measurement period
Exclusions
Patients who died during the measurement period.
Patients who are actively enrolled in multiple plans concurrently as of the end of the measurement period.
Patients who have had a kidney transplant during the measurement period.
Patients who have ESRD.
Patients with a diagnosis of polycystic ovaries who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.
Patients with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.
Public Comments